Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the safety and tolerability of HRS-4642 in patients
with advanced solid tumors harboring KRAS G12D mutation.To estimate the maximum tolerated
dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose [RP2D]) within
investigated subject population groups